For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Growth investors are more concerned with a stock's future prospects, and the overall financial heal ...

Novartis AG (NYSE:NVS) Investor Event at ASCO Conference Call June 2, 2024 7:00 PM ET Company Participants Parag Mahanti - Investor Relations Shreeram Aradhye - President of Global Drug Development and Chief Medical Officer Jeff Legos - Global Head of Oncology & Hematology Drug Development Reshema Kemps-Polanco - Chief Commercial Officer of U.S. Business Rodney Gillespie - International Therapeutic Area Head, Oncology Novartis Conference Call Participants Emmanuel Papadakis - Deutsche Bank Steve Scala - TD ...

Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1 Remibrutinib, an oral Bruton's tyrosine kinase inhibitor, demonstrated a favorable and consistent safety profile up to 1 year, including balanced liver function tests versus placebo1 Novartis intends to submit remibrutinib for approval in chronic spontaneous urticaria (CSU) to global health authorities starting in H2 2024, and continues to inve ...

Novartis (NVS) announced results from the six-month, double-blind trial period of the late-stage APPEAR- C3G study of Fabhalta. Fabhalta, an oral Factor B inhibitor of the alternative complement pathway, is being investigated in adult patients with C3 glomerulopathy (C3G). APPEAR-C3G is a phase III multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of twice-daily oral Fabhalta (200 mg) in C3G patients. The study comprises a six-month double-bl ...

Core Viewpoint - Novartis is currently performing well despite a recent decline in net sales due to the spin-off of its Sandoz business, with strong growth in continuing operations and a positive outlook for future earnings and dividends [3][11][35] Financial Performance - Q1 2023 net sales were $12.953 billion, a 3% increase year-over-year, while Q1 2024 net sales decreased to $11.829 billion, an 8.7% decline due to the Sandoz spin-off [6][9] - Adjusted for the spin-off, net sales from continuing operations grew by 9.5% year-over-year in Q1 2024, with currency-neutral net sales increasing by 11% [11] - Core EPS for Q1 2024 rose by 16.9% to $1.80, exceeding analyst expectations [14] Growth Drivers - Novartis' top 20 brands saw net sales increase by 16% to $9.3 billion in Q1 2024, with 13 out of 20 brands experiencing growth [12][13] - The company has over 100 projects in clinical development and plans to submit more than two dozen indications in core therapeutic areas to regulatory authorities [16][17] Debt and Financial Health - Net debt increased from $10.2 billion to $15.8 billion, primarily due to a $5.2 billion annual dividend payment, but remains manageable [19] - Novartis maintains an AA- credit rating from S&P, indicating strong financial health and stability [20] Valuation and Dividend - Current P/E ratio is 13.8, below the 10-year average of 16.3, suggesting the stock is undervalued [22] - The forward dividend yield is 3.7%, significantly higher than the healthcare sector median of 1.5%, with a consistent annual growth of 6.9% over the last five years [28][30]

Basel, May 25, 2024 – Novartis today presented results from a pre-specified interim analysis of the Phase III ALIGN study of atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, in patients with IgA nephropathy (IgAN)1. Patients treated with atrasentan, in addition to supportive care (maximally tolerated and stable dose of a renin-angiotensin system [RAS] inhibitor), achieved a 36.1% (p<0.0001) reduction in proteinuria (as measured by 24-hour urine protein to creatinine rati ...

EAST HANOVER, N.J., May 25, 2024 /PRNewswire/ -- Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European Renal Association (ERA) Congress1. Patients treated with Fabhalta in addition to supportive care achieved a 35.1% (p=0.0014) reduction in proteinuria (as measured by 24-hour urine protein to creatinine ratio [UPCR]) at 6 months when compared to placebo on top of supportiv ...

New York, USA, May 16, 2024 (GLOBE NEWSWIRE) -- Motor Neuron Disease Clinical Trial Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight Diagnosing motor neuron diseases often presents challenges as there are no definitive tests in many cases. Motor neuron disease symptoms can vary widely among individuals and, in the early stages, may resemble those of other illnesses, complicating diagnosis. However, specific gene tests are available for condit ...

The dividend is just one reason to buy these stocks.There are many reasons to invest in excellent dividend stocks. Such investments are often worth the trouble regardless of whether you're investing for the dividend, or for making capital gains from the robust business (always a laudable goal). But here's the common thread that runs through outstanding dividend stocks: Companies that grow their dividend payouts over extended periods time all have solid fundamentals.The obvious corollary is, not every divide ...

A double beat on the latest quarterly results and raised guidance made investors happy.Scooting past analyst estimates for its latest quarter gave Novartis (NVS 2.27%) a lift on Tuesday. Investors like what they heard about the global healthcare company's inaugural earnings release for 2024, and rewarded Novartis with a more than 2% lift in its stock price today. The shares did better than the S&P 500 index, which had a relatively good trading session with a 1.2% gain.Double beats in the first quarterIn its ...